AbbVie Targets Psychedelic-Based Depression Drug Market With $1.2 Billion Deal
(Tuesday August 26, 2025 @05:20PM (BeauHD)
from the psychedelics-for-profits dept.)
An anonymous reader quotes a report from Reuters:
> AbbVie will [1]buy an experimental depression drug from partner Gilgamesh Pharmaceuticals for up to $1.2 billion , the companies said on Monday, seeking to access a fast-growing market for psychedelic-based treatments. The deal is the latest in the more than $20 billion AbbVie has spent on acquisitions since 2023 for drugs that can drive growth as its flagship rheumatoid arthritis treatment, Humira, lost patent protection. The companies had signed a partnership last year to develop therapies for psychiatric disorders, with privately held Gilgamesh set to receive up to $1.95 billion in option fees and milestone payments. The deals with Gilgamesh, which is also developing treatments for anxiety and post-traumatic stress disorder, also launch AbbVie into the race to develop psychedelic compounds for psychiatric conditions -- a potential $50 billion market, according to Cantor Fitzgerald analyst Josh Schimmer.
>
> The deal, which includes an upfront payment and development milestones, could also bolster AbbVie's neurological conditions portfolio after its experimental schizophrenia drug, which it gained access to through an $8.7 billion purchase of Cerevel Therapeutics, failed in two mid-stage studies last year. Gilgamesh's lead candidate for depression, bretisilocin, activates the 5-HT2A serotonin receptor -- also targeted by classic psychedelics such as psilocybin, found in magic mushrooms, and LSD. The companies said bretisilocin has been shown to exert a shorter duration of psychoactive experience while retaining an extended therapeutic benefit in early and mid-stage studies. AbbVie will advance the drug into late-stage studies.
"Large Pharma has been less active exploring psychedelic compounds due to potential regulatory concerns ... making today's deal more significant," said BMO Capital Markets analyst Evan Seigerman.
[1] https://www.reuters.com/legal/transactional/abbvie-targets-psychedelic-based-depression-drug-market-with-12-billion-deal-2025-08-25/
> AbbVie will [1]buy an experimental depression drug from partner Gilgamesh Pharmaceuticals for up to $1.2 billion , the companies said on Monday, seeking to access a fast-growing market for psychedelic-based treatments. The deal is the latest in the more than $20 billion AbbVie has spent on acquisitions since 2023 for drugs that can drive growth as its flagship rheumatoid arthritis treatment, Humira, lost patent protection. The companies had signed a partnership last year to develop therapies for psychiatric disorders, with privately held Gilgamesh set to receive up to $1.95 billion in option fees and milestone payments. The deals with Gilgamesh, which is also developing treatments for anxiety and post-traumatic stress disorder, also launch AbbVie into the race to develop psychedelic compounds for psychiatric conditions -- a potential $50 billion market, according to Cantor Fitzgerald analyst Josh Schimmer.
>
> The deal, which includes an upfront payment and development milestones, could also bolster AbbVie's neurological conditions portfolio after its experimental schizophrenia drug, which it gained access to through an $8.7 billion purchase of Cerevel Therapeutics, failed in two mid-stage studies last year. Gilgamesh's lead candidate for depression, bretisilocin, activates the 5-HT2A serotonin receptor -- also targeted by classic psychedelics such as psilocybin, found in magic mushrooms, and LSD. The companies said bretisilocin has been shown to exert a shorter duration of psychoactive experience while retaining an extended therapeutic benefit in early and mid-stage studies. AbbVie will advance the drug into late-stage studies.
"Large Pharma has been less active exploring psychedelic compounds due to potential regulatory concerns ... making today's deal more significant," said BMO Capital Markets analyst Evan Seigerman.
[1] https://www.reuters.com/legal/transactional/abbvie-targets-psychedelic-based-depression-drug-market-with-12-billion-deal-2025-08-25/